text size  A   A

Vitreoretinal Surgery

Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg

Bausch + Lomb Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg is the world's first intravitreal drug implant for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Uveitis is an inflammation of the uvea (or uveal layer) – the middle layer of three that make up the eye. It is a treatable condition; however, without proper treatment, it can lead to much more serious conditions such as glaucoma, cataracts, or retinal edema.

Retisert Eye Image

Retisert represents a dramatic advance in the management of chronic noninfectious uveitis affecting the posterior segment of the eye. Now, for the first time, retina and uveitis specialists have the means to provide consistent long-term delivery of a corticosteroid agent, fluocinolone acetonide, precisely where it's needed.

Bausch + Lomb's patented drug-delivery microtechnology in Retisert consists of a tiny drug reservoir designed to deliver sustained levels of the well-known anti-inflammatory corticosteroid, fluocinolone acetonide, for approximately two-and-a-half years (30 months) directly to the back of the eye.

For more information about Retisert, please visit www.retisert.com.

Is This Product Right For You?

Age Group(s)
Condition(s)

Key Features & Benefits

  • Offers long-term control of inflammation
  • Dramatically reduces recurrence rates
  • A straightforward surgical procedure that can be performed in an outpatient hospital setting

Safety Information

As with any surgical procedure there is risk involved. Potential complications accompanying intraocular surgery to place RETISERT into the vitreous cavity may include, but are not limited to, the following: cataract formation, choroidal detachment, temporary decreased visual acuity, endophthalmitis, hypotony, increased intraocular pressure, exacerbation of intraocular inflammation, retinal detachment, vitreous hemorrhage, vitreous loss, and wound dehiscence.

Based on clinical trials with RETISERT, within 34 weeks post implantation approximately 60% of patients will require IOP lowering medications to control intraocular pressure. Within an average post-implantation period of approximately 2 years, approximately 32% of patients are expected to require filtering procedures to control intraocular pressure, and nearly all phakic eyes are expected to develop cataracts and require cataract surgery.

The most frequently reported ocular adverse events in the overall study population were cataract, increased intraocular pressure, procedural complications, and eye pain. These events occurred in approximately 50% to 90% of patients. Procedural complication includes cataract fragments in the eye post-op, implant expulsion, injury, mechanical complication of implant, migration of implant, post-op complications, post-op wound complications, and wound dehiscence.

Related Information

Learn More

For more information about Retisert, please visit www.retisert.com.

For more information about Uveitis, visit The Uveitis Information Group or The Ocular Immunology and Uveitis Foundation.